Fig. 5
Butyrate suppresses iILC2 function in vivo. ILC2s were purified from the colon tissue of control mice. After proliferating in vitro, 5 × 103 cells/well, treated in vitro with 2-200 µM SCFAs for 48 h. (A) IL-13 and IL-4 secretion in supernatant by activated ILC2 measured by ELISA after SCFA treatment. (B) The mRNA levels of IL-13 and IL-4 were tested by quantitative real-time PCR. (C) Cell viability assessed by CCK-8 assay. (D) Representative flow diagram showing PE and Annexin V positive ILC2s after 6-hour treatment. *P < 0.05, **P < 0.01 and ***P < 0.001 (n = 5)